Bimal Shah
Director/Board Member chez ANEBULO PHARMACEUTICALS, INC.
Profil
Bimal R.
Shah currently works at Anebulo Pharmaceuticals, Inc., as Independent Director from 2023 and Allos Therapeutics, Inc., as Chief Financial Officer & Treasurer from 2012.
Mr. Shah also formerly worked at Spectrum Pharmaceuticals, Inc., as Vice President-Corporate & Business Development from 2013 to 2021.
Mr. Shah received his undergraduate degree, graduate degree, and Masters Business Admin degree from Stanford University.
Postes actifs de Bimal Shah
| Sociétés | Poste | Début |
|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Director/Board Member | 05/10/2023 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Director of Finance/CFO | 05/09/2012 |
Anciens postes connus de Bimal Shah
| Sociétés | Poste | Fin |
|---|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2021 |
Formation de Bimal Shah
| Stanford University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Health Technology |
